Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer

NCT ID: NCT02866006

Last Updated: 2022-10-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-10-31
• Study Completion Date: 2022-06-30

Brief Summary

BVAC-C is an immunotherapeutic vaccine using B-Cell and Monocytes as antigen-presenting cells. This study is consists of 2 parts. Phase I is for safety evaluation, and Phase IIa is for efficacy assessment.

Detailed Description

BVAC-C is an immunotherapeutic vaccine using B-Cell and Monocytes as antigen-presenting cells. This study is consists of 2 parts(Phase I, Phase II). Phase I study is Open-label, dose-escalation, multiple dosing study to evaluate the safety, tolerability, immune response and preliminary efficacy of BVAC-C in patients with multiple metastatic progressive or recurrent HPV type 16 or 18 positive cervical cancer after failure to standard care. 9~18 patients will be enrolled In Phase IIa study, which Open-label, sequential assignment multiple dosing study, efficacy, immune response and safety will be evaluated. Total 21 patients will be enrolled in 3 groups.

Conditions

Uterine Cervical Neoplasms

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BVAC-C mono(High dose)

BVAC-C IV injection at 0, 4, 8th weeks.(HIgh dose)

Group Type: EXPERIMENTAL

BVAC-C

Intervention Type: DRUG

Autologous B cells and monocytes transfected with E6E7 gene of HPV

BVAC-C mono(Intermediate dose)

BVAC-C IV injection at 0, 4, 8, 12th weeks.(Half dose)

Group Type: EXPERIMENTAL

BVAC-C

Intervention Type: DRUG

Autologous B cells and monocytes transfected with E6E7 gene of HPV

BVAC-C + Topo Combi

BVAC-C IV injection at 0,4,8,12th weeks.(Half dose) Topotecan IV injection at 2, 6, 10, 14th weeks

Group Type: EXPERIMENTAL

BVAC-C

Intervention Type: DRUG

Autologous B cells and monocytes transfected with E6E7 gene of HPV

Topotecan

Intervention Type: DRUG

Interventions

BVAC-C

Autologous B cells and monocytes transfected with E6E7 gene of HPV

Intervention Type: DRUG

Topotecan

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients with multiple metastatic progressive or recurrent HPV type 16 or 18 positive cervical cancer
• Patients has received 1 or more platinum based doublet chemotherapy as prior therapy for progressive or recurrent tumor lesion (prior therapy does not include platinum chemotherapy given with radiation therapy for 1st line treatment before progression or recurrence)
• Patients with at least 1 measurable lesion according to RECIST
• Female patients between ages of 20 to 70
• Patients with ECOG performance status between 0 to 2
• Patients meets the blood test standards in the screening test

• ANC≥1500/μL
• LLN ≤ALC ≤ULN
• Platelets≥100,000/μL
• Hemoglobin> 9g/dL
• Patients meets the blood chemistry test standards in the screening test

• Serum creatinine ≤ 2.0 mg/dL
• Calculated creatinine clearance ≥ 50 mL/min
• Serum bilirubin ≤1.5 x ULN
• ALT and AST ≤2.5 × ULN (≤ 5 x ULN in patients with liver metastases)
• Patients who has agreed to a medically accepted contraceptive in this clinical trial
• Patients at least three months or more of survival can be expected
• Patients decided to participate in this clinical trial and signed written informed consent

Exclusion Criteria

• Patients histopathology is a neuroendocrine or small cell carcinoma
• Patients with a history of brain metastasis or signs of brain metastasis
• Patients tested positive in serological tests for hepatitis C virus or hepatitis B virus surface antigen, (HBsAg) or human immunodeficiency virus (HIV)
• Patients with a history of HIV infection
• Patients showing abnormal electrocardiogram , including arrhythmia
• Patients have been administered the drug for other clinical trials within 4weeks before the screening visit
• Patients have been administered any vaccines within 4weeks before the screening visit (eg. hepatitis A, hepatitis B, influenza, Td, etc. )
• Patients have been administered the blood products within 3 months before the screening visit
• Patients have received chemotherapy or radiation therapy within 4weeks before the 1st administration of investigational drug (BVAC-C)
• Patients treated with immunosuppressant or immunomodulatory agents within 6 months before the screening visit
• Patients who have participated in the clinical trial of a therapeutic vaccine or immune therapy within 1 year before the screening visit
• Patients with a history of serious allergic disease or serious side effects of the drug
• Patients who is pregnant or breast-feeding
• Patients researchers has determined that participation in the clinical trial is inappropriate
• Patients suspected to have other primary cancer

• Minimum Eligible Age: 20 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Cellid Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

C Y Kang, PH.D

Role: STUDY_CHAIR

Seoul National University

Locations

Samsung Medical Center

Seoul, , South Korea

Countries

South Korea

References

Choi CH, Lee JW, Bae DS, Kang ES, Cho D, Kim YM, Kim K, Kim JW, Kim HS, Kim YT, Lee JY, Lim MC, Oh T, Song B, Jeon I, Park M, Kim WH, Kang CY, Kim BG. Efficacy and safety of BVAC-C in HPV type 16- or 18-positive cervical carcinoma who failed 1st platinum-based chemotherapy: a phase I/IIa study. Front Immunol. 2024 Mar 28;15:1371353. doi: 10.3389/fimmu.2024.1371353. eCollection 2024.

Reference Type: DERIVED

PMID: 38605958 (View on PubMed)

Other Identifiers

BVAC-C-P1

Identifier Type: -

Identifier Source: org_study_id